Roche (China)

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 6.8K citations · Full text

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology · 2021 · 1.5K citations · Full text

Hepatology, Atezolizumab Plus Bevacizumab, Unresectable Hepatocellular Carcinoma +9

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.4K citations

Oncology, Adjuvant Chemotherapy, Pathology +6

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Yoon‐Koo Kang, Won Ki Kang, D.B. Shin et al. · Annals of Oncology · 2009 · 773 citations · Full text

First-line Therapy, Surgical Oncology, Gastrointestinal Oncology +7

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Yi‐Long Wu, Caicun Zhou, Chong Kin Liam et al. · Annals of Oncology · 2015 · 726 citations

Medicine, Phase Iii, Pathology +7